These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16824967)

  • 1. Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI.
    Jia G; Heverhagen JT; Henry H; Polzer H; Baudendistel KT; von Tengg-Kobligk H; Levine AL; Rosol TJ; Knopp MV
    Magn Reson Imaging; 2006 Jul; 24(6):721-5. PubMed ID: 16824967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast enhanced magnetic resonance imaging as a biological marker to noninvasively assess the effect of finasteride on prostatic suburethral microcirculation.
    Jia G; Heverhagen JT; Polzer H; Jacko RV; Liang J; Zhang J; Levine AL; Rosol TJ; Knopp MV
    J Urol; 2006 Nov; 176(5):2299-304. PubMed ID: 17070316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benign prostate hyperplasia: evaluation of treatment response with DCE MRI.
    Heverhagen JT; von Tengg-Kobligk H; Baudendistel KT; Jia G; Polzer H; Henry H; Levine AL; Rosol TJ; Knopp MV
    MAGMA; 2004 Sep; 17(1):5-11. PubMed ID: 15221660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
    Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
    Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis.
    Ren J; Huan Y; Wang H; Chang YJ; Zhao HT; Ge YL; Liu Y; Yang Y
    Clin Radiol; 2008 Feb; 63(2):153-9. PubMed ID: 18194690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benign prostatic hyperplasia: evaluation of T1, T2, and microvascular characteristics with T1-weighted dynamic contrast-enhanced MRI.
    Kershaw LE; Hutchinson CE; Buckley DL
    J Magn Reson Imaging; 2009 Mar; 29(3):641-8. PubMed ID: 19243046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
    Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic gadolinium-enhanced perfusion MRI of prostate cancer: assessment of response to hypofractionated robotic stereotactic body radiation therapy.
    Low RN; Fuller DB; Muradyan N
    AJR Am J Roentgenol; 2011 Oct; 197(4):907-15. PubMed ID: 21940578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of finasteride on prostate tissue composition.
    Marks LS; Partin AW; Dorey FJ; Gormley GJ; Epstein JI; Garris JB; Macairan ML; Shery ED; Santos PB; Stoner E; deKernion JB
    Urology; 1999 Mar; 53(3):574-80. PubMed ID: 10096387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia.
    Memis A; Ozden C; Ozdal OL; Guzel O; Han O; Seckin S
    Urol Int; 2008; 80(2):177-80. PubMed ID: 18362489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
    N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
    Kaplan SA; McConnell JD; Roehrborn CG; Meehan AG; Lee MW; Noble WR; Kusek JW; Nyberg LM;
    J Urol; 2006 Jan; 175(1):217-20; discussion 220-1. PubMed ID: 16406915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of prostate cancer from normal prostate tissue in an animal model: conventional MRI and dynamic contrast-enhanced MRI.
    Gemeinhardt O; Lüdemann L; Prochnow D; Abramjuk C; Taupitz M; Hamm B; Beyersdorff D
    Rofo; 2005 Jul; 177(7):935-9. PubMed ID: 15973594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
    Andersen JT; Wolf H; Ekman P; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
    Ugeskr Laeger; 1996 Sep; 158(36):5030-5. PubMed ID: 8928243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
    Mendichovszky IA; Cutajar M; Gordon I
    Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free-breathing quantitative dynamic contrast-enhanced magnetic resonance imaging in a rat liver tumor model using dynamic radial T(1) mapping.
    Braren R; Curcic J; Remmele S; Altomonte J; Ebert O; Rummeny EJ; Steingoetter A
    Invest Radiol; 2011 Oct; 46(10):624-31. PubMed ID: 21577121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of finasteride (Proscar MSD) on seminal composition, prostate function and fertility in male dogs.
    Iguer-Ouada M; Verstegen JP
    J Reprod Fertil Suppl; 1997; 51():139-49. PubMed ID: 9404280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A method for pharmacokinetic modelling of dynamic contrast enhanced MRI studies of rapidly enhancing lesions acquired in a clinical setting.
    Radjenovic A; Ridgway JP; Smith MA
    Phys Med Biol; 2006 May; 51(9):N187-97. PubMed ID: 16625029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of finasteride on vascular endothelial growth factor.
    Häggström S; Tørring N; Møller K; Jensen E; Lund L; Nielsen JE; Bergh A; Damber JE
    Scand J Urol Nephrol; 2002; 36(3):182-7. PubMed ID: 12201932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
    Granados Loarca EA
    Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.